发布求助
文献互助 智能选刊 最新文献

Drug intelligence & clinical pharmacy最新文献

筛选
英文 中文
Vasopressor effect of epinephrine with and without dopamine during cardiopulmonary resuscitation. 心肺复苏时肾上腺素加与不加多巴胺的血管加压作用。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201105
E R Gonzalez, J P Ornato, R L Levine
{"title":"Vasopressor effect of epinephrine with and without dopamine during cardiopulmonary resuscitation.","authors":"E R Gonzalez,&nbsp;J P Ornato,&nbsp;R L Levine","doi":"10.1177/106002808802201105","DOIUrl":"https://doi.org/10.1177/106002808802201105","url":null,"abstract":"<p><p>We prospectively studied nine prehospital cardiac arrest patients (six M, three F; aged 60 +/- 8 yr) to determine the vasopressor response following incremental (1, 3, and 5 mg) doses of intravenous epinephrine given 5 minutes apart with or without dopamine 15 micrograms/kg/min. All patients were in ventricular fibrillation on arrival of the paramedics and were not resuscitated with standard advanced cardiac life support therapy. Cardiopulmonary resuscitation (CPR) was performed with a computerized Thumper at 60 compressions/min with a 50:50 downstroke-to-upstroke ratio. All patients were intubated and received 12 ventilations/min at a fraction of inspired oxygen of 80 percent. Radial artery pressure was monitored through a #20 gauge radial artery catheter inserted by cutdown within ten minutes after arrival at the emergency room. Five patients received epinephrine alone (group A) and four received epinephrine plus dopamine (group B). The patient's age, paramedic response time, arterial blood gases, and initial diastolic blood pressure (BP) did not differ significantly between treatment groups. Baseline systolic BP was significantly higher (p less than 0.01) in group B (68 +/- 10 mm Hg) than in group A (35 +/- 5 mm Hg). Epinephrine produced a dose-dependent vasopressor response in group A, but not in group B. In group A, peak systolic BP following epinephrine 1, 3, and 5 mg was 57 +/- 20, 69 +/- 23, and 76 +/- 27 mm Hg, respectively (p less than 0.05 for 5 mg vs. baseline). No statistically significant difference was observed among the respective values in group B (81 +/- 13, 80 +/- 18, and 78 +/- 19 mm Hg).(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"868-72"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14364315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Eligibility of inpatients for antibiotic trials. 住院病人接受抗生素试验的资格。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201129
S D Goodwin, W P Hudson, H A Gallis
{"title":"Eligibility of inpatients for antibiotic trials.","authors":"S D Goodwin,&nbsp;W P Hudson,&nbsp;H A Gallis","doi":"10.1177/106002808802201129","DOIUrl":"https://doi.org/10.1177/106002808802201129","url":null,"abstract":"1981;19:213-6. 8. BRAZZELL RK, VANE FM, EHMANN CW, COLBURN WA. Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin PharmacoI1983;24:695-702. 9. BROSEN K, GRAM LF, SCHOU J, LARSEN NE, THAYSSEN P. Dextropropoxyphene kinetics after single and repeated oral doses in man. Eur J Clin PharmacoI1985;29:79-84. 10. CHAN KKH, SAWCHUK RJ, THOMPSON TA, et al. Bioequivalence of carbamazepine chewable and conventional tablets; singledose and steady-state studies. J Pharm Sci 1985;74:866-70.","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"918-9"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14201199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ineffectiveness of continuous quinidine gluconate infusion in the treatment of severe chloroquine-resistant Plasmodium falciparum malaria. 持续输注奎尼丁葡萄糖酸治疗严重氯喹耐药恶性疟原虫疟疾无效。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201110
G K Matsuura, L A Chan
{"title":"Ineffectiveness of continuous quinidine gluconate infusion in the treatment of severe chloroquine-resistant Plasmodium falciparum malaria.","authors":"G K Matsuura,&nbsp;L A Chan","doi":"10.1177/106002808802201110","DOIUrl":"https://doi.org/10.1177/106002808802201110","url":null,"abstract":"<p><p>The drug of choice in the treatment of chloroquine-resistant Plasmodium falciparum malaria is parenteral quinine dihydrochloride. Due to limited use, the drug is not commercially available in the U.S. and must be obtained through the Centers for Disease Control (CDC) in Atlanta, Georgia. As an alternative, the CDC has developed a protocol to treat P. falciparum malaria with parenteral quinidine gluconate. Following this protocol, a 10 mg/kg loading dose of quinidine gluconate followed by a 0.02 mg/kg/min continuous infusion was administered to a 53-year-old man with severe life-threatening chloroquine-resistant P. falciparum malaria. Although the patient described did not survive, the use of parenteral quinidine gluconate still appears to be a viable alternative to parenteral quinine dihydrochloride in the treatment of severe chloroquine-resistant P. falciparum malaria.</p>","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"883-5"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201110","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14202382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
High-dose lorazepam therapy for status epilepticus in a pediatric patient. 大剂量劳拉西泮治疗小儿癫痫持续状态1例。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201112
H M Reincke, R L Gilmore, R J Kuhn
{"title":"High-dose lorazepam therapy for status epilepticus in a pediatric patient.","authors":"H M Reincke,&nbsp;R L Gilmore,&nbsp;R J Kuhn","doi":"10.1177/106002808802201112","DOIUrl":"https://doi.org/10.1177/106002808802201112","url":null,"abstract":"<p><p>This report details the management of status epilepticus with high-dose lorazepam in a 14-year-old patient who was receiving oral clonazepam, ethosuximide, and phenobarbital for an intractable seizure disorder. Although respiratory depression is a frequently cited potential complication of therapy, it did not occur in this patient despite an extraordinarily high total dose of lorazepam, possibly because of tolerance associated with benzodiazepine-receptor down-regulation in this patient's chronic clonazepam therapy. Aggressive dosing of a benzodiazepine may be required for patients receiving chronic benzodiazepine therapy.</p>","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"889-90"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201112","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14364320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Mesna-induced urticaria. Mesna-induced荨麻疹。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201122
C B Pratt, J T Sandlund, W H Meyer, A M Cain
{"title":"Mesna-induced urticaria.","authors":"C B Pratt,&nbsp;J T Sandlund,&nbsp;W H Meyer,&nbsp;A M Cain","doi":"10.1177/106002808802201122","DOIUrl":"https://doi.org/10.1177/106002808802201122","url":null,"abstract":"","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"913-4"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201122","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14278767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Comment: phenytoin and enteral feedings. 评论:苯妥英和肠内喂养。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201131
W E Fitzsimmons, W R Garnett, K A Krueger
{"title":"Comment: phenytoin and enteral feedings.","authors":"W E Fitzsimmons,&nbsp;W R Garnett,&nbsp;K A Krueger","doi":"10.1177/106002808802201131","DOIUrl":"https://doi.org/10.1177/106002808802201131","url":null,"abstract":"a hand sprayer. Practitioner 1977;218:877-83. 3. JOUBERT J, JOUBERT PH. Chorea and psychiatric changes in organophospate poisoning: a report of 2 further cases. S Afr Med J 1988;74:32-4. 4. WEDIN GP, JONES RR. Parenteral administration of hydrocarbons. Clin Toxico/1984;22:485-92. 5. BECK DE, FREEMAN B, MOORE CR. Toxicities with intravenous and subcutaneous administration of a petroleum distillate. Drug Intell Clin Pharm 1981;15:693-4.","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"920"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201131","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14278768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ethylene glycol toxicity--misinterpretation of laboratory data. 乙二醇毒性——对实验室数据的误读。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201126
B M Lomaestro
{"title":"Ethylene glycol toxicity--misinterpretation of laboratory data.","authors":"B M Lomaestro","doi":"10.1177/106002808802201126","DOIUrl":"https://doi.org/10.1177/106002808802201126","url":null,"abstract":"I. SONNENBLICK M, YINNOU A. Mental confusion as a side-effect of ranitidine (letter). Am J Psychiatry 1986;143:257. 2. FINE A, CHURCHILL DN. Potentially lethal interaction of cimetidine and morphine. Can Med Assoc J 1981;124: 1434-5. 3. MOJAVERIAN P, FEDDER IL, VLASSES PH, et al. Cimetidine does not alter morphine disposition in men. Br J Clin Pharmacol 1982;14:809-13. 4. JELLEMA JG. Hallucinations during sustained-release morphine and methadone administration (letter). Lancet 1987;2:392.","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"915-6"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201126","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14363271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Rapid methylprednisolone clearance in a patient with cystic fibrosis. 囊性纤维化患者的甲基强的松龙快速清除率。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201107
C G Green, C K Kraus, R F Lemanske, P M Farrell, W J Jusko
{"title":"Rapid methylprednisolone clearance in a patient with cystic fibrosis.","authors":"C G Green,&nbsp;C K Kraus,&nbsp;R F Lemanske,&nbsp;P M Farrell,&nbsp;W J Jusko","doi":"10.1177/106002808802201107","DOIUrl":"https://doi.org/10.1177/106002808802201107","url":null,"abstract":"<p><p>A pharmacokinetic investigation of administered corticosteroids was conducted in a 16-year-old girl with cystic fibrosis (CF). Equivalent doses of methylprednisolone were given orally and intravenously on consecutive days. Oral bioavailability was essentially 100 percent, ruling out impaired absorption. Drug half-life was shorter and both clearance and volume of distribution were greater in this patient than in normal young adults. From one patient it is impossible to conclude that this unusual disposition of corticosteroids is characteristic of CF. Given the interest in use of corticosteroids in this population, and the examples of other drugs with altered pharmacokinetics in patients with CF, further investigation is warranted.</p>","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"876-8"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14364317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Subcutaneous administration of nifedipine. 硝苯地平皮下注射。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201113
D W Krichbaum, P M Malone
{"title":"Subcutaneous administration of nifedipine.","authors":"D W Krichbaum,&nbsp;P M Malone","doi":"10.1177/106002808802201113","DOIUrl":"https://doi.org/10.1177/106002808802201113","url":null,"abstract":"<p><p>Contents of a 10 mg nifedipine capsule (0.33 ml) were withdrawn by syringe and administered subcutaneously to a patient with hypertensive urgency due to misinterpretation of a physician's order. The drug apparently had its desired hypotensive effect and no adverse effects were noted. The literature on use of nifedipine in hypertensive urgency is reviewed. Subcutaneous administration is not recommended because of a lack of suitable controlled studies and the potential for adverse effects.</p>","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"891-2"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201113","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14364321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Selection of an erythromycin for the treatment of pertussis. 一种红霉素治疗百日咳的选择。
Drug intelligence & clinical pharmacy Pub Date : 1988-11-01 DOI: 10.1177/106002808802201115
M C Nahata
{"title":"Selection of an erythromycin for the treatment of pertussis.","authors":"M C Nahata","doi":"10.1177/106002808802201115","DOIUrl":"https://doi.org/10.1177/106002808802201115","url":null,"abstract":"<p><p>Pertussis is one of the most communicable diseases of the respiratory tract and the incidence of this disease has increased substantially in recent years. Bordetella pertussis is the major pathogen implicated and erythromycin is considered the drug of choice. Because more studies have reported bacteriological and clinical relapses with ethylsuccinate and stearate formulations than with the estolate preparation, erythromycin estolate 50 mg/kg/d in divided doses over a 14-day period is recommended for the treatment of pertussis. None of the studies, however, have directly compared various forms of erythromycin in these patients to establish superiority of one form over the others. Treatment should be initiated as soon as possible and patients should be followed closely to achieve maximal efficacy and minimize the spread of the disease.</p>","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 11","pages":"895-8"},"PeriodicalIF":0.0,"publicationDate":"1988-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802201115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14202383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信